Low-dose methotrexate in myeloproliferative neoplasm models

• Kavitha Chinnaiya,
• Michelle A. Lawson,
• Sally Thomas,
• Marie-Therese Haider,
• Jenny Down,
• Andrew D. Chantry,
• David Hughes,
• Antony Green,
• Jon R. Sayers,
• John A. Snowden,
• Martin P. Zeidler

Affiliations

Kavitha Chinnaiya

The Bateson Centre, Department of Biomedical Science, The University of Sheffield, UK

Michelle A. Lawson

Department of Oncology & Metabolism, The University of Sheffield, UK

Sally Thomas

The Bateson Centre, Department of Biomedical Science, The University of Sheffield, UK

Marie-Therese Haider

Department of Oncology & Metabolism, The University of Sheffield, UK

Jenny Down

Department of Oncology & Metabolism, The University of Sheffield, UK

Andrew D. Chantry

Department of Oncology & Metabolism, The University of Sheffield, UK

David Hughes

Department of Histopathology, Sheffield Teaching Hospitals NHS Foundation Trust, UK

Antony Green

Cambridge Stem Cell Institute, Cambridge institute for Medical Research and Department of Haematology, University of Cambridge, UK

Jon R. Sayers

Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, UK

John A. Snowden

Department of Oncology & Metabolism, The University of Sheffield, UK;Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, UK

Martin P. Zeidler

The Bateson Centre, Department of Biomedical Science, The University of Sheffield, UK